Safety and Preliminary Efficacy of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #FR-OR035; Pres time: Nov 7, 2025; 05:40 PM - 05:50 PM; Location: Room 310A, Convention Center; P2 | "Fatalities were associated with possible pre-existing co-morbidities or underlying LN disease characteristics. Preliminary efficacy results indicate encouraging clinical activity in pts with Class III/IV ± V LN receiving 60 mg zeto."
Clinical • P2b data • Cardiovascular • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Samir V. Parikh; Neel K Anand; Shraddha Desai; Eric Lowe; Tony Muchamuel; Kiruthi Palaniswamy; Rachel Peterson; Kathryn Ray; Zung P To; Jennifer Whang; Richard Leff
|